Terms: = Prostate cancer AND ACVR1, SKR1, 90, ENSG00000115170, Q04771, ACVRLK2, FOP, ALK2, ACTRI
7823 results:
1. Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.
Rosar F; Burgard C; David S; Marlowe RJ; Bartholomä M; Maus S; Petto S; Khreish F; Schaefer-Schuler A; Ezziddin S
Sci Rep; 2024 May; 14(1):11271. PubMed ID: 38760451
[TBL] [Abstract] [Full Text] [Related]
2. Circular RNAs in EMT-driven metastasis regulation: modulation of cancer cell plasticity, tumorigenesis and therapy resistance.
Ashrafizadeh M; Dai J; Torabian P; Nabavi N; Aref AR; Aljabali AAA; Tambuwala M; Zhu M
Cell Mol Life Sci; 2024 May; 81(1):214. PubMed ID: 38733529
[TBL] [Abstract] [Full Text] [Related]
3. An untargeted analytical workflow based on Kendrick mass defect filtering reveals dysregulations in acylcarnitines in prostate cancer tissue.
Cerrato A; Aita SE; Biancolillo A; Laganà A; Marini F; Montone CM; Rosati D; Salciccia S; Sciarra A; Taglioni E; Capriotti AL
Anal Chim Acta; 2024 Jun; 1307():342574. PubMed ID: 38719419
[TBL] [Abstract] [Full Text] [Related]
4. Faster both in operative time and functional recovery by the extraperitoneal daVinci SP-based robot-assisted radical prostatectomy: a propensity score matching analysis compared to transperitoneal multiport counterpart.
Ko YH; Jang JY; Kim YU; Kim SW
J Robot Surg; 2024 May; 18(1):205. PubMed ID: 38714543
[TBL] [Abstract] [Full Text] [Related]
5. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.
Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Carmignani L; De Cobelli O; Mischinger J; Ahyai S; Karakiewicz PI
World J Urol; 2024 Apr; 42(1):269. PubMed ID: 38679642
[TBL] [Abstract] [Full Text] [Related]
6. Breakthrough electroneutron multi-response miniature dosimetry/spectrometry in medical accelerator.
Sohrabi M; Malekitakbolagh M; Nedaei HA
Sci Rep; 2024 Apr; 14(1):9557. PubMed ID: 38664481
[TBL] [Abstract] [Full Text] [Related]
7. Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using
Muralidhar A; Hernandez R; Morris ZS; Comas Rojas H; Bio Idrissou M; Weichert JP; McNeel DG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38663936
[TBL] [Abstract] [Full Text] [Related]
8. [Study on the efficacy and complications of patients undergoing radical surgery and radical radiotherapy for localized prostate cancer].
Shi XQ; Wang SH; Liu Z; Lu LW; Xu S; Fu D; Cheng W
Zhonghua Nan Ke Xue; 2023 Oct; 29(10):910-915. PubMed ID: 38639661
[TBL] [Abstract] [Full Text] [Related]
9. Racial Differences in Germline Genetic Testing Completion Among Males With Pancreatic, Breast, or Metastatic prostate cancers.
Shevach JW; Candelieri-Surette D; Lynch JA; Hubbard RA; Alba PR; Glanz K; Parikh RB; Maxwell KN
J Natl Compr Canc Netw; 2024 Apr; 22(4):237-243. PubMed ID: 38631387
[TBL] [Abstract] [Full Text] [Related]
10. MRI-based monitoring of prostate cancer after HIFU: Inter-reader agreement and diagnostic performance of the PI-FAB score.
Pausch AM; Elsner C; Rupp NJ; Eberli D; Hötker AM
Eur J Radiol; 2024 Jun; 175():111463. PubMed ID: 38615502
[TBL] [Abstract] [Full Text] [Related]
11. Unmet supportive care needs among cancer patients: exploring cancer entity-specific needs and associated factors.
Springer F; Mehnert-Theuerkauf A; Gebhardt C; Stolzenburg JU; Briest S
J Cancer Res Clin Oncol; 2024 Apr; 150(4):190. PubMed ID: 38607426
[TBL] [Abstract] [Full Text] [Related]
12. [The mediating effect of coping style between illness perception and fear of cancer recurrence in patients undergoing radical prostatectomy].
Yan QQ; Yao X; Liu YC; Zhou JR; Cai J; Wu ZG; Jiang HH; Li HY
Zhonghua Nan Ke Xue; 2023 Jun; 29(6):511-517. PubMed ID: 38602723
[TBL] [Abstract] [Full Text] [Related]
13. Provider Perceptions of an Electronic Health Record prostate cancer Screening Tool.
Carlsson SV; Preston M; Vickers A; Malhotra D; Ehdaie B; Healey M; Kibel AS
Appl Clin Inform; 2024 Mar; 15(2):282-294. PubMed ID: 38599619
[TBL] [Abstract] [Full Text] [Related]
14. High-dose-rate Brachytherapy Monotherapy in Patients With Localised prostate cancer: Dose Modelling and Optimisation Using Computer Algorithms.
Dabic-Stankovic K; Rajkovic K; Stankovic J; Marosevic G; Kolarevic G; Pavicar B
Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):378-389. PubMed ID: 38584072
[TBL] [Abstract] [Full Text] [Related]
15. prostate Health Index (PHI) as a triage tool for reducing unnecessary magnetic resonance imaging (MRI) in patients at risk of prostate cancer.
Agnello L; Vidali M; Salvaggio G; Agnello F; Lo Sasso B; Gambino CM; Ciaccio M
Clin Biochem; 2024 May; 127-128():110759. PubMed ID: 38583655
[TBL] [Abstract] [Full Text] [Related]
16. Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study.
Hietikko R; Mirtti T; Kilpeläinen TP; Tolonen T; Räisänen-Sokolowski A; Nordling S; Hannus J; Laurila M; Taari K; Tammela TLJ; Autio R; Natunen K; Auvinen A; Rannikko A
World J Urol; 2024 Apr; 42(1):217. PubMed ID: 38581590
[TBL] [Abstract] [Full Text] [Related]
17. Prediction of false-positive PI-RADS 5 lesions on prostate multiparametric MRI: development and internal validation of a clinical-radiological characteristics based nomogram.
Cheng Y; Fan B; Fu Y; Yin H; Lu J; Li D; Li X; Qiu X; Guo H
BMC Urol; 2024 Apr; 24(1):76. PubMed ID: 38566091
[TBL] [Abstract] [Full Text] [Related]
18. Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium.
Bührer E; D'Haese D; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Collette L; Gillessen S; Beyer J
Eur J Cancer; 2024 May; 202():114042. PubMed ID: 38564927
[TBL] [Abstract] [Full Text] [Related]
19. Optimizing PSMA scintigraphy for resource limited settings - a retrospective comparative study.
Kolade OU; Brink A; Ayeni AO; More S; Holness J
Cancer Imaging; 2024 Apr; 24(1):46. PubMed ID: 38556864
[TBL] [Abstract] [Full Text] [Related]
20. Decision regret of cancer patients after radiotherapy: results from a cross-sectional observational study at a large tertiary cancer center in Germany.
Rühle A; Wieland L; Hinz A; Mehnert-Theuerkauf A; Nicolay NH; Seidel C
J Cancer Res Clin Oncol; 2024 Mar; 150(3):167. PubMed ID: 38546873
[TBL] [Abstract] [Full Text] [Related]
[Next]
